|
1
|
Li X, Zheng R, Li X, Shan H, Wu Q, Wang Y
and Chen W: Trends of incidence rate and age at diagnosis for
cervical cancer in China, from 2000 to 2014. Chin J Cancer Res.
29:477–486. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cao S, Liu W, Li F, Zhao W and Qin C:
Decreased expression of lncRNA GAS5 predicts a poor prognosis in
cervical cancer. Int J Clin Exp Pathol. 7:6776–6783.
2014.PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cancer Genome Atlas Research Network,
Albert Einstein College of Medicine, Analytical Biological
Services, Barretos Cancer Hospital, Baylor College of Medicine,
Beckman Research Institute of City of Hope, Buck Institute for
Research on Aging, Canada's Michael Smith Genome Sciences Centre,
Harvard Medical School, Helen F. Graham Cancer Center &Research
Institute at Christiana Care Health Services, ; et al: Integrated
genomic and molecular characterization of cervical cancer. Nature.
543:378–384. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
WHO Guidelines Approved by the Guidelines
Review Committee, . Comprehensive cervical cancer control: a guide
to essential practice. 2nd. World Health Organization; Geneva:
2014
|
|
6
|
Du PL, Wu KS, Fang JY, Zeng Y, Xu ZX, Tang
WR, Xu XL and Lin K: Cervical cancer mortality trends in China,
1991–2013, and predictions for the future. Asian Pac J Cancer Prev.
16:6391–6396. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang J, Li G, Wang Y, Tang S, Sun X, Feng
X, Li Y, Bao G, Li P, Mao X, et al: Suppression of tumor
angiogenesis by metformin treatment via a mechanism linked to
targeting of HER2/HIF-1α/VEGF secretion axis. Oncotarget.
6:44579–44592. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Noman MZ, Desantis G, Janji B, Hasmim M,
Karray S, Dessen P, Bronte V and Chouaib S: PD-L1 is a novel direct
target of HIF-1α, and its blockade under hypoxia enhanced
MDSC-mediated T cell activation. J Exp Med. 211:781–790. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wigerup C, Påhlman S and Bexell D:
Therapeutic targeting of hypoxia and hypoxia-inducible factors in
cancer. Pharmacol Ther. 164:152–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jussila L and Alitalo K: Vascular growth
factors and lymphangiogenesis. Physiol Rev. 82:673–700. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rocha SF, Schiller M, Jing D, Li H, Butz
S, Vestweber D, Biljes D, Drexler HC, Nieminen-Kelhä M, Vajkoczy P,
et al: Esm1 modulates endothelial tip cell behavior and vascular
permeability by enhancing VEGF bioavailability. Circ Res.
115:581–590. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao K, Song X, Huang Y, Yao J, Zhou M, Li
Z, You Q, Guo Q and Lu N: Wogonin inhibits LPS-induced tumor
angiogenesis via suppressing PI3K/Akt/NF-κB signaling. Eur J
Pharmacol. 737:57–69. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hosaka M, Watari H, Takeda M, Moriwaki M,
Hara Y, Todo Y, Ebina Y and Sakuragi N: Treatment of cervical
cancer with adjuvant chemotherapy versus adjuvant radiotherapy
after radical hysterectomy and systematic lymphadenectomy. J Obstet
Gynaecol Res. 34:552–556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Siva S, Herschtal A, Thomas JM, Bernshaw
DM, Gill S, Hicks RJ and Narayan K: Impact of post-therapy positron
emission tomography on prognostic stratification and surveillance
after chemoradiotherapy for cervical cancer. Cancer. 117:3981–3988.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee HJ, Kim YS, Shin SS, Nam JH, Kim YT,
Han S and Choi EK: Long-term outcomes of concomitant
chemoradiotherapy incorporating high-dose-rate brachytherapy to
treat locally advanced cervical cancer. Tumori. 98:615–621. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Casagrande N, De Paoli M, Celegato M,
Borghese C, Mongiat M, Colombatti A and Aldinucci D: Preclinical
evaluation of a new liposomal formulation of cisplatin, lipoplatin,
to treat cisplatin-resistant cervical cancer. Gynecol Oncol.
131:744–752. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Agyemang K, Han L, Liu E, Zhang Y, Wang T
and Gao X: Recent advances in astragalus membranaceus anti-diabetic
research: pharmacological effects of its phytochemical
constituents. Evid Based Complement Alternat Med. 2013:6546432013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun T, Wang J, Huang LH and Cao YX:
Antihypertensive effect of formononetin through regulating the
expressions of eNOS, 5-HT2A/1B receptors and α1-adrenoceptors in
spontaneously rat arteries. Eur J Pharmacol. 699:241–249. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ha H, Lee HY, Lee JH, Jung D, Choi J, Song
KY, Jung HJ, Choi JS, Chang SI and Kim C: Formononetin prevents
ovariectomy-induced bone loss in rats. Arch Pharm Res. 33:625–632.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huh JE, Nam DW, Baek YH, Kang JW, Park DS,
Choi DY and Lee JD: Formononetin accelerates wound repair by the
regulation of early growth response factor-1 transcription factor
through the phosphorylation of the ERK and p38 MAPK pathways. Int
Immunopharmacol. 11:46–54. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu Y, Zhang X, Li Z, Yan H, Qin J and Li
T: Formononetin inhibits human bladder cancer cell proliferation
and invasiveness via regulation of miR-21 and PTEN. Food Funct.
8:1061–1066. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou R, Xu L, Ye M, Liao M, Du H and Chen
H: Formononetin inhibits migration and invasion of MDA-MB-231 and
4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through
PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 [-Delta Delta C(T)] method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lachenmayer A, Toffanin S, Cabellos L,
Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC,
Thung S, et al: Combination therapy for hepatocellular carcinoma:
additive preclinical efficacy of the HDAC inhibitor panobinostat
with sorafenib. J Hepatol. 56:1343–1350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Waggoner SE: Cervical cancer. Lancet.
361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mahasiripanth T, Hokputsa S, Niruthisard
S, Bhattarakosol P and Patumraj S: Effects of Acanthus ebracteatus
Vahl on tumor angiogenesis and on tumor growth in nude mice
implanted with cervical cancer. Cancer Manag Res. 4:269–279.
2012.PubMed/NCBI
|
|
27
|
Eckert AW, Lautner MH, Schütze A, Taubert
H, Schubert J and Bilkenroth U: Coexpression of hypoxia-inducible
factor-1α and glucose transporter-1 is associated with poor
prognosis in oral squamous cell carcinoma patients. Histopathology.
58:1136–1147. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shi D, Guo W, Chen W, Fu L, Wang J, Tian
Y, Xiao X, Kang T, Huang W and Deng W: Nicotine promotes
proliferation of human nasopharyngeal carcinoma cells by regulating
α7AChR, ERK, HIF-1α and VEGF/PEDF signaling. PLoS One.
7:e438982012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen Y, Liu BL, Shang B, Chen AS, Liu SQ,
Sun W, Yin HZ, Yin JQ and Su Q: Nutrition support in surgical
patients with colorectal cancer. World J Gastroenterol.
17:1779–1786. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kayl AE and Meyers CA: Side-effects of
chemotherapy and quality of life in ovarian and breast cancer
patients. Curr Opin Obstet Gynecol. 18:24–28. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu W and Xiao Z: Formononetin induces
apoptosis of human osteosarcoma cell line U2OS by regulating the
expression of Bcl-2, Bax and MiR-375 in vitro and in vivo. Cell
Physiol Biochem. 37:933–939. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ren J, Xu HJ, Cheng H, Xin WQ, Chen X and
Hu K: Synthesis and antitumor activity of formononetin nitrogen
mustard derivatives. Eur J Med Chem. 54:175–187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen J and Sun L: Formononetin-induced
apoptosis by activation of Ras/p38 mitogen-activated protein kinase
in estrogen receptor-positive human breast cancer cells. Horm Metab
Res. 44:943–948. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim
YO, Jung MH, Ock MS and Cha HJ: Elevated expression of thymosin β4,
vascular endothelial growth factor (VEGF), and hypoxia inducible
factor (HIF)-1α in early-stage cervical cancers. Pathol Oncol Res.
17:493–502. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bachtiary B, Schindl M, Pötter R, Dreier
B, Knocke TH, Hainfellner JA, Horvat R and Birner P: Overexpression
of hypoxia-inducible factor 1alpha indicates diminished response to
radiotherapy and unfavorable prognosis in patients receiving
radical radiotherapy for cervical cancer. Clin Cancer Res.
9:2234–2240. 2003.PubMed/NCBI
|
|
36
|
Birner P, Schindl M, Obermair A, Plank C,
Breitenecker G and Oberhuber G: Overexpression of hypoxia-inducible
factor 1alpha is a marker for an unfavorable prognosis in
early-stage invasive cervical cancer. Cancer Res. 60:4693–4696.
2000.PubMed/NCBI
|
|
37
|
Chen WT, Huang CJ, Wu MT, Yang SF, Su YC
and Chai CY: Hypoxia-inducible factor-1alpha is associated with
risk of aggressive behavior and tumor angiogenesis in
gastrointestinal stromal tumor. Jpn J Clin Oncol. 35:207–213. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jin YM, Xu TM, Zhao YH, Wang YC and Cui
MH: In vitro and in vivo anti-cancer activity of formononetin on
human cervical cancer cell line HeLa. Tumour Biol. 35:2279–2284.
2014. View Article : Google Scholar : PubMed/NCBI
|
